Company profile
T2 Biosystems, Inc.
OTC: TTOO · Healthcare · Medical - Diagnostics & Research
#670 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 72GM —SS 45
v0.1 · 25/100 weight · pillars only
↑ disclosure history, filing timeliness · ↓ revenue growth (YoY), market scale
Methodology →Revenue TTM
$7.7M
Rev growth YoY (TTM)
-30.2%
Net income (FY)
-$50.1M
Employees
113
as of 2026-08-28
Market cap
$28.0k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$7.2M$7.2M2023
Net income-$50.1M-$50.1M2023
Operating income-$49.7M-$49.7M2023
Total assets$34.8M$34.8M2023
Liabilities$62.8M$62.8M2023
Equity-$28.0M-$28.0M2023
Revenue trend
FY2019 – FY2023 · USD
FY19
FY19
FY19
FY19
FY20
FY21
FY22
FY23
Revenue by segment
Filed disclosures · FY2023
By product
Product48%
Product Consumables35%
Product Instruments10%
Service3%
Contribution Revenue3%
Instrument Rentals1%
By geography
Non-US68%
ITALY33%
The read
What is T2 Biosystems, Inc.’s revenue?
T2 Biosystems, Inc. booked $7.2M in FY2023 revenue, contracting 68% year over year — slower than 86% of Healthcare companies we track, at a -696.2% net margin.
Peers · Healthcare
Newtopia Inc.——Syra Health Corp. Class A Common Stock51DMedical Imaging Corp.——Whitehawk Therapeutics Inc50DImmunome, Inc.47DINVO Fertility, Inc.43DNeighbors
Middlesex →Key facts
CEOCraig R. Jalbert
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersLexington, MA
ExchangeOTC: TTOO
Employees113
IPO date2014-08-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.